Search results for "Highlights"
PPIs not associated with mortality risk for most causes, study finds
While patients who took proton-pump inhibitors (PPIs) had significantly higher risks of all-cause mortality and mortality due to cancer, cardiovascular diseases, respiratory diseases, and digestive diseases, lag times of up to six years attenuated these associations so they were no longer statistically significant.
https://gastroenterology.acponline.org/archives/2022/07/22/1.htm
22 Jul 2022
Spotlight on PPIs and cancer
Recent studies assessed the association between proton-pump inhibitors (PPIs) and cancer, as well as the effects of PPI treatment after a cancer diagnosis.
https://gastroenterology.acponline.org/archives/2021/07/23/5.htm
23 Jul 2021
Education for patients reduced upper GI endoscopies for uninvestigated dyspepsia
To reduce overuse, a Dutch trial provided a self-managed, web-based educational intervention containing information on gastric function, dyspepsia, and upper GI tract endoscopy to some patients referred for the procedure by their primary care clinicians.
https://gastroenterology.acponline.org/archives/2021/05/28/3.htm
28 May 2021
Noninvasive score for fibrotic NASH designed for, validated in primary care settings
Levels of aspartate aminotransferase, high-density lipoprotein cholesterol, and HbA1c can be used to predict which patients might need referral to a subspecialist for fibrotic nonalcoholic steatohepatitis (NASH).
https://gastroenterology.acponline.org/archives/2022/04/22/1.htm
22 Apr 2022
Use of PPIs may be associated with C. difficile infections
A Danish nationwide cohort study found that ongoing exposure to proton-pump inhibitors (PPIs) was associated with moderately increased community-associated Clostridioides difficile infection risk during treatment and for up to one year afterward.
https://gastroenterology.acponline.org/archives/2021/03/26/3.htm
26 Mar 2021
AGA issues guidelines on use of intragastric balloon therapy for patients with obesity
Intragastric balloon therapy can be considered as a weight loss intervention in patients with obesity who have not seen success with conventional therapies, according to the American Gastroenterological Association (AGA).
https://gastroenterology.acponline.org/archives/2021/04/23/2.htm
23 Apr 2021
Practice guidance addresses vascular liver disorders, portal vein thrombosis, procedural bleeding
Among other statements, the American Association for the Study of Liver Diseases said that modifiable risk factors for bleeding, such as use of antithrombotic drugs, should be identified and corrected before procedures in patients with cirrhosis.
https://gastroenterology.acponline.org/archives/2020/12/18/2.htm
18 Dec 2020
Half of overweight, obese adults may have fatty liver disease
The global prevalence of metabolic dysfunction-associated fatty liver disease, a newly proposed term for nonalcoholic fatty liver disease, is “astonishingly high,” the authors of a recent meta-analysis found.
https://gastroenterology.acponline.org/archives/2021/02/26/3.htm
26 Feb 2021
Urgent endoscopy did not improve outcomes from acute upper GI bleeds
Thirty-day mortality was slightly lower among high-risk patients who underwent endoscopy for an acute upper GI bleed within 24 hours of a consult instead of within six hours, although the difference was not statistically significant.
https://gastroenterology.acponline.org/archives/2020/04/24/3.htm
24 Apr 2020
Mailed FIT screening for CRC effective, cost-effective in safety-net population
Patients at a federally qualified health center system in Central Texas who were not up to date on colorectal cancer (CRC) screening were mailed a packet containing an introductory letter, a fecal immunochemical test (FIT), easy-to-read instructions, and a postage-paid lab mailer.
https://gastroenterology.acponline.org/archives/2021/05/28/2.htm
28 May 2021